257 related articles for article (PubMed ID: 23771131)
1. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
[TBL] [Abstract][Full Text] [Related]
2. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
3. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia.
Ruggieri R
Phys Med Biol; 2004 Oct; 49(20):4811-23. PubMed ID: 15566177
[TBL] [Abstract][Full Text] [Related]
5. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
6. The impact of hypofractionation on simultaneous dose-boosting to hypoxic tumor subvolumes.
Ruggieri R; Nahum AE
Med Phys; 2006 Nov; 33(11):4044-55. PubMed ID: 17153384
[TBL] [Abstract][Full Text] [Related]
7. Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.
Lindblom E; Antonovic L; Dasu A; Lax I; Wersäll P; Toma-Dasu I
Radiat Oncol; 2014 Jun; 9():149. PubMed ID: 24974778
[TBL] [Abstract][Full Text] [Related]
8. Applying a hypoxia-incorporating TCP model to experimental data on rat sarcoma.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1603-8. PubMed ID: 22270163
[TBL] [Abstract][Full Text] [Related]
9. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
10. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
11. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia.
Ruggieri R; Naccarato S; Nahum AE
Acta Oncol; 2010 Nov; 49(8):1304-14. PubMed ID: 20500031
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia Induced by Vascular Damage at High Doses Could Compromise the Outcome of Radiotherapy.
Lindblom EK; Dasu A; Toma-Dasu I
Anticancer Res; 2019 May; 39(5):2337-2340. PubMed ID: 31092425
[TBL] [Abstract][Full Text] [Related]
14. Volume dependence in hypoxia-targeted dose escalation.
Chvetsov AV; Zeng J; Rajendran JG
Med Phys; 2018 Nov; 45(11):5325-5331. PubMed ID: 30192391
[TBL] [Abstract][Full Text] [Related]
15. Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy.
Scheenstra AE; Rossi MM; Belderbos JS; Damen EM; Lebesque JV; Sonke JJ
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):224-8. PubMed ID: 24331668
[TBL] [Abstract][Full Text] [Related]
16. Lung V20 measurements: In regard to Seppenwoolde et al. (Int J Radiat Oncol Biol Phys 2003;55:724-735), and Tsujino et al. (Int J Radiat Oncol Biol Phys 2003;56:1208-1209).
Garces YI; Miller RC
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1636; author reply 1636-7. PubMed ID: 15050346
[No Abstract] [Full Text] [Related]
17. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
[TBL] [Abstract][Full Text] [Related]
18. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
19. The relative significance of repopulation and hypoxic clonogens in the fractionated radiotherapy of a mouse tumor.
Urano M; Nishimura Y; Yaes R
Radiat Res; 1995 May; 142(2):204-11. PubMed ID: 7724736
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
